Dosage Information for Monjuvi: Form, Potency, Method of Administration, and other Details
Monjuvi, a biologic drug, is a treatment option for adults with diffuse large B-cell lymphoma (DLBCL), a type of cancer that affects the body's immune system [1]. The drug, known as tafasitamab-cxix, is administered in combination with lenalidomide (Revlimid), another medication.
The typical dosage for Monjuvi in adults with DLBCL is 12 mg of Monjuvi per kilogram (kg) of body weight. This dosage is based on body weight to ensure effective treatment [1].
The initial treatment cycle of Monjuvi lasts 28 days. In the first three weeks, Monjuvi is given as an intravenous infusion weekly on days 1, 8, and 15. After the first cycle, the treatment is administered every two weeks [1].
Lenalidomide, given orally, is taken once daily on days 1–21 of each 28-day cycle. The combination treatment with Monjuvi and lenalidomide may continue for up to 12 cycles, after which the doctor may recommend continuing treatment with Monjuvi only [1].
Monjuvi comes as a powder that is mixed into a solution and given as an IV infusion. It is essential to monitor infusions closely for infusion-related reactions, and the infusion may be interrupted or discontinued depending on severity [1].
Common side effects of Monjuvi treatment include myelosuppression (reduced bone marrow function) and infections, such as neutropenia (low white blood cell count) [1]. For this reason, monitoring for these side effects is necessary.
Your doctor may also recommend taking premedications before Monjuvi to help prevent side effects. Examples of premedications include acetaminophen (Tylenol), diphenhydramine (Benadryl), and prednisone (Rayos) [1].
To ensure that you do not miss your Monjuvi appointments, using a medication reminder can be helpful. If you miss an appointment for your Monjuvi dose, call your doctor's office right away to reschedule [1].
It's essential to note that the dosages provided in this article are typical and may not be the same for every patient. Factors such as other medical conditions can affect the prescribed dosage [1].
For additional information about Monjuvi, including side effects, cost, and more, refer to related articles. As Monjuvi is not available in a biosimilar version, it's crucial to discuss any concerns with your healthcare provider [1].
[1] Monjuvi Prescribing Information. Seattle Genetics, Inc. [Accessed 10 March 2023]. Available at: https://www.monjuvi.com/prescribing-information/
- Monjuvi, a drug used in oncology, is approved for treating non-Hodgkin's lymphoma, specifically diffuse large B-cell lymphoma (DLBCL), a type of cancer that impairs the immune system.
- The drug, tafasitamab-cxix, is administered in combination with lenalidomide (Revlimid) in adults with DLBCL, with the typical dosage being 12 mg of Monjuvi per kg of body weight.
- The initial treatment cycle of Monjuvi lasts 28 days, with weekly intravenous infusions on days 1, 8, and 15, followed by every-two-week treatments. Lenalidomide, an oral medication, is taken once a day on days 1–21 of each cycle.
- Monitoring for common side effects of Monjuvi, such as myelosuppression and infections, is essential, and premedications like acetaminophen, diphenhydramine, and prednisone may be recommended to prevent these reactions.
- It's crucial to discuss any concerns about Monjuvi, including costs and additional medical information, with a healthcare provider, as the drug is not available in a biosimilar version.
